Multikinase inhibitors (TKIs), such as lucitanib (E-3810, NCT01283945), dovitinib (TKI258), nintedanib, and ponatinib [42], and selective FGFR inhibitors, such as AZD4547 [18] (NCT00979134, NCT01202591), BGJ398 (NCT01004224), LY2874455 (NCT01212107), and JNJ-42756493 (NCT01703481), have been tested in several phase I and II trials in cancers with FGFR1 aberrations [10]. Here, FGFR1 is linked to cancer.